Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00330083 · ClinicalTrials.gov registry record · Phase 1

Safety of ALK Ragweed Tablet

A Phase 1 study, sponsored by ALK-Abelló A/S.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT00330083 is a Phase 1 study that has completed, run by ALK-Abelló A/S. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00330083, a Phase 1 study, has completed, sponsored by ALK-Abelló A/S.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Interventions

  • BIOLOGICAL ALK Ragweed Tablet

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2006-05
Phase Phase 1

Sponsor

ALK-Abelló A/S

5 total trials

What the Registry Record Tells You About NCT00330083

The ClinicalTrials.gov registry entry for NCT00330083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALK-Abelló A/S, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ALK Ragweed Tablet is the first listed.

NCT00330083 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00330083 about?

NCT00330083 is a clinical study titled "Safety of ALK Ragweed Tablet". This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

What is the current status of trial NCT00330083?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2006-05.

What interventions are being tested in trial NCT00330083?

The interventions under investigation include: ALK Ragweed Tablet (BIOLOGICAL).

Who is sponsoring clinical trial NCT00330083?

This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.